|
Malignant neoplasm of prostate
|
0.360 |
Biomarker
|
disease |
BEFREE |
Thus, in prostate cancer, CtBP1-regulated miR-34a modulates STMN1 expression and is involved in cancer progression through the CtBP1miR-34aSTMN1GDF15 axis.<b>Implications:</b> The CtBP1miR-34aSTMN1GDF15 axis is a potential therapeutic target for treatment of aggressive prostate cancer.<i></i>.
|
29025958 |
2018 |
|
Malignant neoplasm of prostate
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that PDEF may inhibit prostate cancer progression by transcriptional downregulation of oncogenic STMN expression.
|
22378487 |
2012 |
|
Malignant neoplasm of prostate
|
0.360 |
Biomarker
|
disease |
BEFREE |
Targeting stathmin in prostate cancer.
|
16373697 |
2005 |
|
Malignant neoplasm of prostate
|
0.360 |
Biomarker
|
disease |
BEFREE |
We recently showed that adenovirus-mediated gene transfer of anti-stathmin ribozyme could suppress the malignant phenotype of prostate cancer cells in vitro.
|
17172428 |
2006 |
|
Malignant neoplasm of prostate
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Stathmin/oncoprotein 18, a protein that regulates microtubule dynamics, is highly expressed in a number of tumors including leukemia, lymphoma, neuroblastoma, breast, ovarian, and prostate cancers.
|
20816848 |
2011 |
|
Glioma
|
0.350 |
Biomarker
|
disease |
BEFREE |
siRNA targeting stathmin inhibits invasion and enhances chemotherapy sensitivity of stem cells derived from glioma cell lines.
|
25348735 |
2014 |
|
Glioma
|
0.350 |
Biomarker
|
disease |
BEFREE |
PHAP1 promotes glioma cell proliferation by regulating the Akt/p27/stathmin pathway.
|
29667783 |
2018 |
|
Glioma
|
0.350 |
Biomarker
|
disease |
BEFREE |
From our data we conclude an inhibitory function of TPT1-AS1 in glioma cell autophagy by downregulating miR-770-5p and upregulating STMN1, which may be instrumental for the therapeutic targeting and clinical management of glioma.
|
31637705 |
2020 |
|
Glioma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of stathmin suppressed neoangiogenesis of glioma and provides a potential target for glioma treatment.
|
22038457 |
2012 |
|
Glioma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Moreover, Malat1 abolished the suppression effects of miR-101 on glioma cell autophagy and proliferation, which involved in upregulating the expression of miR-101 targets STMN1, RAB5A and ATG4D.
|
28834690 |
2017 |
|
Carcinoma
|
0.330 |
Biomarker
|
group |
BEFREE |
These findings suggest that ERK-mediated Op18/stathmin is involved in taxol resistance of tumors; blockage of ERK signal improves the sensitivity of tumor cells to taxol, which provides new clues for treating taxol-resistant carcinomas.
|
26881937 |
2016 |
|
Carcinoma
|
0.330 |
AlteredExpression
|
group |
BEFREE |
Stathmin was present in a wide variety of endocrine tumors and was most highly expressed in rapidly proliferating tumors including anaplastic thyroid carcinomas, Merkel cell carcinomas of the skin and small cell carcinomas of the lung.
|
18461287 |
2008 |
|
Carcinoma
|
0.330 |
Biomarker
|
group |
BEFREE |
Loss of stathmin in MMTV-Δ16HER2 transgenic mice decreased the incidence and increased the latency of these very aggressive mammary carcinomas.
|
30478213 |
2019 |
|
Mental Depression
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
The best model included baseline depression severity and expression of STMN1 and miR-5695 and predicted TWSI with area under the curve = 0.94 (P < .001).
|
31087825 |
2019 |
|
Mental Depression
|
0.320 |
Biomarker
|
disease |
BEFREE |
Expression of p16(INK4a) and STMN1 was directly correlated with anxiety scores in the depression group, and that of p16(INK4a), STMN and TERT with the depression and anxiety scores in the combined sample (MDD plus controls).
|
23185405 |
2012 |
|
Depressive disorder
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
The best model included baseline depression severity and expression of STMN1 and miR-5695 and predicted TWSI with area under the curve = 0.94 (P < .001).
|
31087825 |
2019 |
|
Depressive disorder
|
0.320 |
Biomarker
|
disease |
BEFREE |
Expression of p16(INK4a) and STMN1 was directly correlated with anxiety scores in the depression group, and that of p16(INK4a), STMN and TERT with the depression and anxiety scores in the combined sample (MDD plus controls).
|
23185405 |
2012 |
|
Prostatic Neoplasms
|
0.320 |
Biomarker
|
group |
BEFREE |
Given the role of stathmin-1 in the destabilization of microtubles and taxane resistance, the Ggamma-globin-Tag model and other SV40/T-antigen driven transgenic models may be useful for testing potential therapies directed at stathmin-1 in human prostate tumors.
|
20058236 |
2010 |
|
Prostatic Neoplasms
|
0.320 |
AlteredExpression
|
group |
BEFREE |
Stathmin levels increase early during normal mouse prostate development and again during prostate tumor development and progression.
|
17455228 |
2007 |
|
Malignant Glioma
|
0.310 |
Biomarker
|
disease |
BEFREE |
The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas.
|
17440165 |
2007 |
|
Mammary Neoplasms
|
0.310 |
AlteredExpression
|
group |
BEFREE |
We examined 50 human primary breast tumours for stathmin mRNA and protein expression and screened for abnormalities in the chromosome region harbouring the stathmin gene.
|
9743287 |
1998 |
|
Amyotrophic Lateral Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The importance of the SMN genes in the genetics of sporadic ALS.
|
19922137 |
2010 |
|
Amyotrophic Lateral Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Supporting this, we found that increasing SMN across all MN populations using an Nedd8-activating enzyme inhibitor promotes survival in both SMA and ALS-derived MNs.
|
28178525 |
2017 |
|
Amyotrophic Lateral Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we demonstrate that SMN protein is significantly reduced in the spinal cords of patients with sporadic ALS.
|
24210254 |
2014 |
|
Amyotrophic Lateral Sclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, we sequenced SMN genes to determine if SMN mutations were more prevalent in patients with ALS.
|
22323753 |
2012 |